Programmed cell death-1 (PD-1) receptor expression on tumor cells and programmed death-ligand 1 (PD-L1) expression on TILs are therefore indicators of the enrichment of the adaptive immune response against tumor cells. The gene discussed is PDCD1; the disease is neoplasm.